Stock FBRX FORTE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Forte Biosciences, Inc. Stock

Equities

FBRX

US34962G1094

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
0.745 USD +2.41% Intraday chart for Forte Biosciences, Inc. +4.33% -9.33%
Mar. 18 Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 05 Camac Partners Provides Information to Shareholders CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 27.11M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 9
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.13%
More Fundamentals * Assessed data

Chart Forte Biosciences, Inc.

Dynamic Chart

Latest news about Forte Biosciences, Inc.

Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Camac Partners Provides Information to Shareholders CI
Forte Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Tocagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Forte Biosciences Filed a Motion to Dismiss the Amended Complaint CI
Camac Fund Files an Amended Class Action and Derivative Complaint CI
Declaration of Voting Results by Forte Biosciences CI
Declaration of Voting Results by Forte Biosciences CI
Declaration of Voting Results by Forte Biosciences CI
Declaration of Voting Results by Forte Biosciences CI
Declaration of Voting Results by Forte Biosciences CI
Forte Biosciences, Inc. Announces Directorate Appointments CI
Institutional Shareholder Services and Glass Lewis Support Camac Partners CI
Camac Partners Shares Key Facts that Reinforce the Need for Urgent Change in Forte Biosciences?s Boardroom CI
Forte Biosciences Issues an Investor Presentation to Shareholders CI
More news

Analyst Recommendations on Forte Biosciences, Inc.

FORTE BIOSCIENCES : Chardan Capital Upgrades Forte Biosciences to Neutral From Sell Following Recent Selloff, Adjusts Price Target to $3.50 From $4 MT
FORTE BIOSCIENCES : Ladenburg Thalmann Downgrades Forte Biosciences to Neutral From Buy MT
FORTE BIOSCIENCES : Brookline Capital Downgrades Forte Biosciences to Hold from Buy MT
FORTE BIOSCIENCES : Chardan Downgrades Forte Biosciences to Sell From Buy, Adjusts Price Target to $4 From $105; Shares Slide 80% Premarket MT
FORTE BIOSCIENCES : Ladenburg Thalmann Downgrades Forte Biosciences to Neutral from Buy MT
More recommendations

Press releases Forte Biosciences, Inc.

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update BU
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules BU
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update BU
ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual Meeting BU
Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s Boardroom BU
More press releases

Quotes and Performance

1 day+2.41%
1 week+4.33%
Current month+0.50%
1 month+2.05%
3 months+18.25%
6 months+69.40%
Current year-9.33%
More quotes

Highs and lows

1 week
0.71
Extreme 0.71
0.77
1 month
0.63
Extreme 0.6301
0.78
Current year
0.44
Extreme 0.44
0.85
1 year
0.38
Extreme 0.38
1.11
3 years
0.38
Extreme 0.38
43.57
5 years
0.38
Extreme 0.38
53.99
10 years
0.38
Extreme 0.38
53.99
More quotes

Managers and Directors - Forte Biosciences, Inc.

Managers TitleAgeSince
Paul Wagner CEO
 Chief Executive Officer 53 16-12-31
Anthony Riley DFI
 Director of Finance/CFO 57 20-02-29
Christopher Roenfeldt COO
 Chief Operating Officer - 20-09-30
Members of the board TitleAgeSince
David Gryska BRD
 Director/Board Member 68 23-01-09
Steven Kornfeld BRD
 Director/Board Member 56 20-05-31
Stephen Doberstein BRD
 Director/Board Member 65 22-05-11
More insiders

Quotes

Date Price Change Volume
24-05-10 0.745 +2.41% 3,536
24-05-09 0.7275 -3.00% 8,251
24-05-08 0.75 +5.50% 13,497
24-05-07 0.7109 -1.26% 10,400
24-05-06 0.72 +0.83% 11,555

Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT

More quotes

Company Profile

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Sector
Biotechnology & Medical Research
Calendar
2024-05-12 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.745 USD
Average target price
2.875 USD
Spread / Average Target
+285.91%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
FORTE BIOSCIENCES, INC. Stock Forte Biosciences, Inc.
-9.33% 27.11M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
ARGENX SE Stock argenx SE
+1.28% 22.25B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
GENMAB A/S Stock Genmab A/S
-7.05% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. FBRX Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW